Calvive 1000 effervescent tablets

Country: United Kingdom

Bahasa: Inggeris

Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)

Bahan aktif:

Calcium lactate gluconate; Calcium carbonate

Boleh didapati daripada:

Haleon UK Ltd

Kod ATC:

A12AA20

INN (Nama Antarabangsa):

Calcium lactate gluconate; Calcium carbonate

Dos:

2.263gram ; 1.75gram

Borang farmaseutikal:

Effervescent tablet

Laluan pentadbiran:

Oral

Kelas:

No Controlled Drug Status

Jenis preskripsi:

Valid as a prescribable product

Ringkasan produk:

BNF: 09050101; GTIN: 5012131744000

Risalah maklumat

Pharma code XXXX
Read all of this leaflet carefully because it
contains important information for you.
This medicine is available without prescription.
However, you still need to take Calvive carefully to
get the best results from it.
• Keep this leaflet. You may need to read it again.
• Ask your pharmacist if you need more
information or advice.
• If any of the side effects gets serious, or if you
notice any side effects not listed in this leaflet,
please tell your doctor or pharmacist.
In this leaflet
1. What Calvive is and what it is used for
2. Before you take Calvive
3. How to take Calvive
4. Possible side effects
5. How to store Calvive
6. Further information
1.
WHAT CALVIVE IS AND WHAT IT IS
USED FOR
Calvive contains a rich source of calcium which
is an essential mineral, necessary for bone
formation and maintenance.
Calvive is used in the prevention and treatment of
calcium deficiency, and may be used, with other
medicines, to prevent and treat a condition called
osteoporosis (weakening of the bones).Calvive
is also used, together with vitamin D
3
, for the
treatment of rickets (softening of growing bones
in children) and osteomalacia (softening of adults
bones).
Calcium is absorbed from the intestine and
distributed throughout the body in the blood.
Calcium plays an important role in several body
functions. It is essential for nerve, muscle and
heart function as well as for the clotting of blood.
In addition, it is necessary for many hormones
to work properly in the body. To carry out these
various roles, calcium must be available in the
appropriate concentration.
2.
BEFORE YOU TAKE CALVIVE
Do not take Calvive...
• If you are allergic to calcium and any of the
other ingredients of Calvive (see the list of
ingredients in section 6 at the end of the
leaflet).
• If you are suffering from raised levels of blood
calcium (hypercalcaemia);
• If you are suffering from increased calcium in
your urine (hypercalciuria);
• If you are suffering from certain kidney
problems including: kidney stones
(neph

Ciri produk

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Calvive 1000 Effervescent Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each effervescent tablet of 1000 mg contains 2263 mg of calcium
lactate gluconate
and 1750 mg of calcium carbonate (equivalent to 1000 mg or 25 mmol of
calcium).
Excipients with known effect
Each effervescent tablet of 1000 mg contains 30 mg of aspartame (E
951),
136.90 mg of sodium (5.95 mmol), 30 mg of orange flavour powder
(containing
630 microgram sorbitol (E 420), 180 nanogram of benzyl alcohol, 210
nanogram
sulphur dioxide (E 220) and 13.08 mg glucose).
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Effervescent tablet
White, circular, flat faced, bevelled edge effervescent tablets with
an orange odour
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
- Prevention and treatment of calcium deficiency
- Calcium supplement as an adjunct to specific therapy in the
prevention and
treatment of osteoporosis
- Rickets and osteomalacia, in addition to vitamin D
3
therapy
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults and children: 1000mg per day.
The effervescent tablets should be dissolved in a glass of water
(approx. 200
ml) and drunk immediately. Calvive 1000 effervescent tablet may be
taken
with or without food.
4.3
CONTRAINDICATIONS
- Hypersensitivity to the active substances or to any of the
excipients listed in
section 6.1 of the effervescent tablet
- Diseases and/or conditions resulting in hypercalcaemia and/or
hypercalciuria
- Nephrocalcinosis, nephrolithiasis
4.4. SPECIAL WARNINGS AND PRECAUTIONS
FOR USE
For patients with mild hypercalciuria (exceeding 300 mg/24 hours or
7.5 mmol/24
hours), or with a history of urinary calculi, monitoring of calcium
excretion
in the urine is required. If necessary, the calcium dose should be
reduced or
therapy should be discontinued. An increased fluid intake is
recommended for
patients prone to formation of calculi in the urinary tract.
In patients with impaired renal function, calcium salts should be